Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03
February 02 2022 - 4:30PM
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) whose mission is to
focus on unmet needs and apply proven science and new technology to
revolutionize treatment for patients, starting with eye care, today
announced that it will host a live webcast on Tuesday, February 8th
at 9 a.m. pacific time for a corporate update and to provide expert
clinical perspectives on Demodex blepharitis (DB) and the potential
of TP-03 to treat this disease. The approximately 60-minute webcast
will include presentations from Bobak Azamian, M.D., Ph.D,
President and Chief Executive Officer of Tarsus; Eric Donnenfeld,
M.D.; Paul Karpecki, O.D.; and Elizabeth Yeu, M.D, Chief Medical
Advisor for Tarsus.
The agenda for the webcast will be as follows:
Welcome and Introductions |
David Nakasone |
Tarsus: Positioned for a Transformational
Year |
Bobak Azamian |
Prevalence and Impact of Demodex Blepharitis |
Eric Donnenfeld |
Diagnosis and Unmet Need |
Paul Karpecki |
Real World Demodex Blepharitis Case Studies |
Eric Donnenfeld and Paul Karpecki |
TP-03 Clinical Data Review |
Elizabeth Yeu |
What’s Ahead |
Bobak Azamian |
Questions and Answers |
All |
Interested parties may access the webcast here or at the events
section of the Tarsus website. A replay will be available for a
limited time at the same address.
About TP-03TP-03 (lotilaner ophthalmic
solution, 0.25%) is a novel, investigational therapeutic designed
to resolve the signs of Demodex blepharitis by targeting and
eradicating the root cause of the disease – Demodex mite
infestation. Lotilaner is a well-characterized anti-parasitic agent
that paralyzes and eradicates Demodex mites by selectively
inhibiting the GABA-Cl channels. It is a highly lipophilic
molecule, which may promote its uptake in the oily sebum of the
hair follicle where the mites reside. TP-03 was evaluated in the
pivotal Saturn-1 (Phase 2b/3) trial involving 421 patients and
successfully met the primary and secondary endpoints with no
serious treatment-related adverse events and was well tolerated.
TP-03 is currently being evaluated in the Saturn-2 (Phase 3)
pivotal trial. If approved, TP-03 may potentially offer treatment
for millions of patients around the world with Demodex
blepharitis.
About Demodex BlepharitisBlepharitis is a
common lid margin disease that is characterized by eyelid margin
inflammation, redness and ocular irritation. Demodex blepharitis is
caused by an infestation of Demodex mites, the most common
ectoparasite found on humans and accounts for over two-thirds of
all blepharitis cases. Demodex blepharitis may affect as many as 25
million Americans based on an extrapolation from the Titan study
indicating 58% of patients presenting to U.S. eye care clinics have
collarettes, a pathognomonic sign of Demodex infestation, and that
at least 45 million people annually visit an eye care clinic.
Demodex blepharitis can have a significant clinical burden and
negatively impact patients’ daily lives. The Titan study also
showed that current management tools, such as tea tree oil and lid
wipes, are ineffective at treating Demodex blepharitis. Currently,
there are no FDA-approved treatments for Demodex blepharitis.
About Tarsus Pharmaceuticals, Inc.Tarsus
Pharmaceuticals, Inc. applies proven science and new technology to
revolutionize treatment for patients, starting with eye care. It is
advancing its pipeline to address several diseases with high unmet
need across a range of therapeutic categories, including eye care,
dermatology, and infectious disease prevention. The company is
studying two investigational medicines in clinical trials. Its lead
product candidate, TP-03, is a novel therapeutic being studied in a
second Phase 3 pivotal trial for the treatment of Demodex
blepharitis. TP-03 is also being developed for the treatment of
Meibomian Gland Disease. Tarsus is developing TP-05, an oral,
non-vaccine therapeutic for the prevention of Lyme disease, which
is currently being studied in a Phase 1b clinical trial.
Forward-Looking StatementsStatements in this
press release about future expectations, plans and prospects, as
well as any other statements regarding matters that are not
historical facts, may constitute “forward-looking statements.”
These statements include statements regarding the market size for
TP-03 and TP-05, future events and Tarsus’ plans for and the
anticipated benefits of its product candidates including TP-03,
TP-04 and TP-05, the timing, objectives and results of the clinical
trials, anticipated regulatory and development milestones, future
financial condition and position, and the quotations of Tarsus’
management. The words, without limitation, “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “might,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” or “would,” or the negative of these
terms or other similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these or similar identifying words. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important factors
and are detailed from time to time in the reports Tarsus files with
the Securities and Exchange Commission, including Tarsus’ Form 10-K
for the year ended December 31, 2020 filed on March 31, 2021 and
the most recent Form 10-Q quarterly filing for the quarter ending
September 30, 2021 filed on November 10, 2021 with the SEC, which
Tarsus incorporates by reference into this press release, copies of
which are posted on its website and are available from Tarsus
without charge. However, new risk factors and uncertainties may
emerge from time to time, and it is not possible to predict all
risk factors and uncertainties. Accordingly, readers are cautioned
not to place undue reliance on these forward-looking statements.
Any forward-looking statements contained in this press release are
based on the current expectations of Tarsus’ management team and
speak only as of the date hereof, and Tarsus specifically disclaims
any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.
Contacts: Media Contact:SuJin Oh
twelvenote(917) 841-5213soh@twelvenote.com
Investor Contact:David NakasoneHead of Investor Relations(949)
620-3223DNakasone@tarsusrx.com
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Apr 2023 to Apr 2024